Neos

shire
Pharma

Shire scores FDA nod for Mydayis, its latest Adderall iteration

Shire nabbed FDA approval Wednesday for its new long-acting ADHD drug Mydayis, and it's targeting $500 million in sales by 2020.
Tracy Staton Jun 21, 2017 10:32am
FDAApprovedStamp

Neos, facing critics, snags another pediatric ADHD nod

Jun 20, 2017 11:35am